Microfluidic Biochip for Rapid Hemoglobin Disorder Diagnosis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for diagnosing hemoglobin disorders like sickle cell disease are costly, time-consuming, and inaccessible in low-income countries, leading to high mortality rates due to the lack of early and equitable diagnosis.

Innovation Solution

A biochip system that includes an electrophoresis biochip with a housing, buffer ports, a sample loading port, and electrodes, using cellulose acetate paper saturated with an alkaline buffer solution, and an imaging system for visualizing and quantifying hemoglobin variants, allowing for rapid and accurate diagnosis of hemoglobin disorders using a small blood sample.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If traditional hemoglobin screening methods are used, then diagnostic accuracy is maintained, but the cost and time required increase significantly, making them inaccessible in low-income countries

Engineering Contradiction:
Improvecost-effectivenessVSAvoiddiagnosis time
Core Design Contradiction:
Ease of manufactureVSLoss of time

Solution Approach 1:

The patent employs disposable microfluidic chips with integrated electrophoresis channels and detection zones that are inexpensive to manufacture and use. These single-use chips eliminate the need for expensive, reusable equipment while maintaining diagnostic accuracy, making the system cost-effective for low-income settings.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention replaces complex mechanical laboratory equipment with a simplified microfluidic-electrophoresis system that uses electric fields for separation and optical detection for analysis. This substitution reduces mechanical complexity and maintenance requirements while accelerating the diagnosis process.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If traditional hemoglobin screening methods are used, then comprehensive analysis is achieved, but the time required extends to 2-6 weeks, preventing timely intervention

Engineering Contradiction:
Improvediagnosis speedVSAvoidhemoglobin variant detection accuracy
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The microfluidic chip is pre-designed with optimized electrophoresis channels, buffer reservoirs, and detection zones that are prepared in advance. The alkaline buffer solution is pre-loaded into the chip, eliminating preparation time and enabling immediate analysis upon sample introduction, thus achieving rapid diagnosis without compromising precision.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention changes the operating parameters by using high-voltage electrophoresis (rapid separation) combined with sensitive optical detection methods. This parameter optimization reduces analysis time from weeks to minutes while maintaining or improving detection accuracy for hemoglobin variants.

Inventive Principle:
Principle #35Parameter changes

3Ease of operation

If skilled personnel are required to operate traditional tests, then diagnostic reliability is maintained, but the complexity of operation increases, limiting accessibility

Engineering Contradiction:
Improveoperational simplicityVSAvoiddiagnosis reliability
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The microfluidic chip is designed as a self-contained system that performs buffer loading, sample processing, electrophoresis separation, and result detection automatically. The integrated design eliminates the need for skilled operators to perform complex manual procedures, making the system easy to operate while maintaining reliable diagnostic results through standardized protocols.

Inventive Principle:
Principle #25Self-service

4Quantity of substance

If extensive blood samples are used for analysis, then comprehensive hemoglobin profile is obtained, but the sample volume requirement increases, complicating point-of-care testing

Engineering Contradiction:
Improveblood sample volumeVSAvoidhemoglobin variant quantification accuracy
Core Design Contradiction:
Quantity of substanceVSMeasurement precision

Solution Approach 1:

The invention segments the blood sample analysis into distinct microfluidic zones within the chip, including separation channels, detection regions, and waste collection areas. This segmentation allows efficient use of minimal sample volume (microliter scale) while maintaining comprehensive hemoglobin profile analysis through spatially resolved detection of different variants.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables rapid, cost-effective, and accurate diagnosis of hemoglobin disorders, including sickle cell disease, with results obtainable in minutes, suitable for point-of-care settings, thereby reducing mortality rates by facilitating early intervention.

Implementation Method 1

The first electrode and the second electrode can generate an electric field across the cellulose acetate paper effective to promote migration of hemoglobin variants in the blood sample along the cellulose acetate paper

Methodology Applied
Scientific EffectElectrophoresis: Electrophoresis

Data Source

PatentEP4063481A1Biochips to diagnose hemoglobin disorders and monitor blood cells
Publication Date: 2022.09.28 CASE WESTERN RESERVE UNIV
  • EP4063481A1 patent drawingFigure 1A~1E
  • EP4063481A1 patent drawingFigure 2A~2B
  • EP4063481A1 patent drawingFigure 3A~3B

AI summary

A biochip compatible with very small blood sample volumes is used for detecting for detecting hemoglobin disorders and monitoring disorders associated with aberrant blood cell deformability and adhesion, including disease severity, upcoming pain crisis, treatment response, and treatment effectiveness in a clinically meaningful way.